{"nctId":"NCT03242018","briefTitle":"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control","startDateStruct":{"date":"2017-08-16","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease Stage 4"],"count":277,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Sotagliflozin"]},{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sotagliflozin"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Sotagliflozin","otherNames":["SAR439954"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Participants with Type 2 Diabetes (drug-naïve or on antidiabetic therapy) and documented severe renal insufficiency - CKD4 - defined by an estimated glomerular filtration rate (eGFR) equation (based on the 4 variable modification of diet in renal disease (MDRD) equation) of ≥15 and \\<30 milliliter per minute (mL/min)/1.73 per meter square (m\\^2).\n* Signed written informed consent to participate in the study in accordance with local regulations.\n\nExclusion criteria:\n\n* At the time of screening, age \\<18 years.\n* Hemoglobin A1c (HbA1c) \\<7% or \\>11%.\n* Type 1 diabetes.\n* Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy during the study.\n* Treatment with an sodium-glucose cotransporter type 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin, empagliflozin) during the last 12 months.\n* Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such as heart failure, active cancer, or other conditions that the Investigator believes with result in a short life expectancy, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.\n* Lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at Randomization.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo","description":"An analysis of covariance (ANCOVA) model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.151"},{"groupId":"OG001","value":"-0.40","spread":"0.131"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 200 mg Versus Placebo","description":"An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.151"},{"groupId":"OG001","value":"-0.07","spread":"0.162"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.069","spread":"0.4482"},{"groupId":"OG001","value":"-0.291","spread":"0.5056"},{"groupId":"OG002","value":"-0.644","spread":"0.4348"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 26","description":"An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.615"},{"groupId":"OG001","value":"-0.43","spread":"0.480"},{"groupId":"OG002","value":"-1.02","spread":"0.490"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SBP at Week 12 in Participants With Baseline SBP ≥130 mmHg","description":"An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.70","spread":"1.815"},{"groupId":"OG001","value":"-4.84","spread":"1.882"},{"groupId":"OG002","value":"-7.10","spread":"1.842"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SBP at Week 12 for All Participants","description":"An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"1.762"},{"groupId":"OG001","value":"-5.74","spread":"1.752"},{"groupId":"OG002","value":"-7.86","spread":"1.794"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g)","description":"An ANCOVA model was used for analysis. No Measure of Dispersion was pre-specified to be calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"NA"},{"groupId":"OG001","value":"-26.99","spread":"NA"},{"groupId":"OG002","value":"-30.66","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <6.5% at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"5.4","spread":null},{"groupId":"OG002","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0% at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"17.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participants or clinical investigation participants administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"81.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Hypoglycemic Events","description":"Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \\[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\\]; Severe \\[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\\] or documented symptomatic hypoglycemia \\[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null},{"groupId":"OG001","value":"40.4","spread":null},{"groupId":"OG002","value":"38.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"28.7","spread":null},{"groupId":"OG002","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"30.9","spread":null},{"groupId":"OG002","value":"27.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":93},"commonTop":["Urinary tract infection","Glomerular filtration rate decreased","Vitamin D deficiency","Hyperkalaemia","Renal impairment"]}}}